KSQ Therapeutics
KSQ Therapeutics is dedicated to curing human diseases by leveraging gene-editing and CRISPR/Cas9 technology to discover and develop transformative medicines. Their mission is to drive cures in hard-to-treat diseases, focusing initially on cancer, with a pipeline of innovative therapeutics including eTIL® programs and a platform called CRISPRomics®. The company aims to overcome significant challenges in solid tumor treatment and is committed to scientific excellence, collaboration, and patient-focused innovation.
Industries
Nr. of Employees
medium (51-250)
KSQ Therapeutics
Patents
Products
Engineered tumor-infiltrating lymphocyte (eTIL) therapeutic candidates
Autologous engineered T cell therapy candidates generated by editing patient-derived tumor-infiltrating lymphocytes to enhance tumor infiltration and anti-tumor activity for solid tumor indications.
Engineered tumor-infiltrating lymphocyte (eTIL) therapeutic candidates
Autologous engineered T cell therapy candidates generated by editing patient-derived tumor-infiltrating lymphocytes to enhance tumor infiltration and anti-tumor activity for solid tumor indications.
Services
Partnering with pharmaceutical companies and research organizations to co-develop and commercialize cell therapy programs and therapeutic candidates.
Platform-driven discovery of therapeutic targets via genome-wide functional screens and preclinical validation to support therapeutic candidate creation.
Partnering with pharmaceutical companies and research organizations to co-develop and commercialize cell therapy programs and therapeutic candidates.
Platform-driven discovery of therapeutic targets via genome-wide functional screens and preclinical validation to support therapeutic candidate creation.
Expertise Areas
- Functional genomic target discovery
- Cell therapy engineering and development
- Translational immunology and immune monitoring
- Preclinical in vivo efficacy testing
Key Technologies
- CRISPR/Cas9 gene editing
- Genome-wide CRISPR screening
- Tumor-infiltrating lymphocyte (TIL) engineering
- Engineered T cell therapies